Table 2.
Efficacy of vaccination in field trials for various etiologies on postweaning mortalitya
| Mortality, % | ||||
|---|---|---|---|---|
| Control | Vaccinated | Absolute difference, % | Relative difference, % | |
| Actinobacillus pleuropneumoniae | ||||
| Habrun et al. (2002) | 5.8 | 1.0 | 4.8 | 82.8 |
| Del Pozo Sacristan et al. (2014) | 4.0 | 1.4 | 2.6 | 65.0 |
| Glasserella parasuis b | ||||
| McOrist et al. (2009) | 1.4–2.1 | 0.5–0.9 | — | — |
| Lawsonia intracellularis | ||||
| Almond et al. (2006) | 17.5 | 1.6 | 15.9 | 90.9 |
| Deitmer et al. (2011) | 3.3 | 3.2 | 0.1 | 3.0 |
| Peiponen et al. (2018) | 6.5 | 7.4 | −0.9 | −13.8 |
| Mycoplasma hyopneumoniae | ||||
| Bilic et al. (1996) | 3.1 | 0.0 | 3.1 | 100.0 |
| Maes et al. (1998) | 9.2 | 9.1 | 0.1 | 1.1 |
| Maes et al. (1999) | 4.0 | 3.8 | 0.2 | 5.0 |
| Pallares et al. (2000)c | 3.6 | 1.4 | 2.2 | 61.1 |
| Stipkovits et al. (2003) | 9.4 | 5.1 | 4.3 | 45.7 |
| Holyoake et al. (2006) | 4.2 | 3.8 | 0.4 | 9.5 |
| Tzivara et al. (2007) | 11.9 | 8.1 | 3.8 | 31.9 |
| Tassis et al. (2012) | 9.0 | 6.6d | 2.4 | 26.7 |
| Kristensen et al. (2014)e | 2.2 | 2.5f | −0.3 | −13.6 |
| Kristensen et al. (2014)g | 3.0 | 3.3f | −0.3 | −10.0 |
| PCV2 | ||||
| Cline et al. (2008) | 7.8 | 2.1 | 5.7 | 73.1 |
| Fachinger et al. (2008) | 8.7 | 6.6 | 2.1 | 24.1 |
| Horlen et al. (2008) | 18.4 | 9.0 | 9.4 | 51.1 |
| Kixmoller et al. (2008) | 7.5 | 3.5 | 4.0 | 53.3 |
| Desrosiers et al. (2009) | 9.5 | 2.4 | 7.1 | 74.7 |
| Neumann et al. (2009) | 10.4 | 5.0 | 5.4 | 51.9 |
| Segales et al. (2009) | 17.0 | 9.5 | 7.5 | 44.1 |
| Pejsak et al. (2010) | 28.8 | 16.1 | 12.7 | 44.1 |
| Takahagi et al. (2010)h | 20.8 | 12.1 | 8.7 | 41.8 |
| Takahagi et al. (2010)i | 26.5 | 13.7 | 12.8 | 48.3 |
| Takahagi et al. (2010)j | 14.7 | 14.1 | 0.6 | 4.1 |
| Jacela et al. (2011) | 5.9 | 3.1 | 2.8 | 47.5 |
| Venegas-Vargas et al. (2011) | 6.9 | 2.9 | 4.0 | 58.0 |
| Young et al. (2011) | 7.2 | 2.6 | 4.6 | 63.9 |
| Fraile et al. (2012) | 7.0 | 4.9 | 2.1 | 30.0 |
| Lee et al. (2012) | 32.2 | 8.0 | 24.2 | 75.2 |
| Potter et al. (2012) | 7.0 | 6.8 | 0.2 | 2.9 |
| Han et al. (2013) | 26.7 | 6.7 | 20.0 | 74.9 |
| Heibenberger et al. (2013) | 11.4 | 4.0 | 7.4 | 64.9 |
| Sidler et al. (2012) | 10.0 | 4.2 | 5.8 | 58.0 |
| Velasova et al. (2013) | 5.5 | 4.7 | 0.8 | 14.5 |
| Potter et al. (2014) | 11.0 | 7.8 | 3.2 | 29.1 |
| Jeong et al. (2015) | 16.7 | 11.1 | 5.6 | 33.5 |
| Martelli et al. (2016) | 13.4 | 9.9 | 3.5 | 26.1 |
| Villa-Mancera et al. (2016) | 26.5 | 8.3 | 18.2 | 68.7 |
| Czyzewska-Dors et al. (2018) | 5.3 | 5.0 | 0.3 | 5.7 |
| PRRSV | ||||
| Mavromatis et al. (1999) | 7.5 | 3.4 | 4.1 | 54.7 |
| Park et al. (2014) | 18.3 | 1.3 | 17.0 | 92.9 |
| Jeong et al. (2018) | 10.0 | 3.3 | 6.7 | 67.0 |
| Streptococcus suis | ||||
| Pejsak et al. (2001) | 4.7 | 2.3 | 2.4 | 51.1 |
| Hopkins et al. (2019)k | — | — | — | 21.0 |
aInformation could not be gathered for etiologies not listed in table. Values provided to illustrate the range in observed responses across studies and not intended to make scientific interpretation. Thus, results of statistical hypothesis testing is not provided.
bFormerly Haemophilus parasuis.
cAverage of all site types.
dIntramuscular vaccine treatment including both nursery and finishing periods.
eNursery portion of publication.
fAverage of two vaccination treatments using separate commercial vaccines.
gFinisher portion of publication.
hRepresents PCV2a-2 portion of investigation.
iRepresents PCV2b portion of investigation.
jRepresents PCV2a-1 portion of investigation.
k Hopkins et al. (2019) reported that administration of an autogenous Streptococcus suis vaccination reduced relative nursery mortality by 21%; however, did not provide specific estimates.